Exact Sciences raises 2025 revenue guidance to $3.235B amid Cologuard Plus expansion and Cancerguard launch (NASDAQ:EXAS)
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...